Introduction
bladder cancer, muscle-invasive bladder cancer
BLADDER CANCER
There will be an estimated 81 180 bladder cancer diagnoses in the US in 2022, with approximately 75% being non–muscle-invasive bladder cancer (NMIBC).Sequential intravesical gemcitabine and docetaxel was initially described in 2015 as an effective and well-tolerated therapy after BCG failure, yielding 2-year recurrence-free survival (RFS) of 34% to 46%.